S&P 500   3,970.90 (+1.78%)
DOW   31,900.27 (+2.04%)
QQQ   292.20 (+1.22%)
AAPL   142.33 (+3.45%)
MSFT   259.44 (+2.72%)
FB   194.68 (+0.59%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.63 (-0.18%)
NIO   15.73 (-4.32%)
AMD   93.80 (+0.32%)
CGC   5.17 (-6.34%)
MU   69.22 (+0.46%)
T   20.84 (+2.16%)
GE   75.91 (+0.88%)
F   12.83 (+2.64%)
DIS   104.87 (+2.39%)
AMC   11.59 (-3.66%)
PFE   52.96 (+0.93%)
PYPL   81.10 (+0.70%)
NFLX   184.85 (-0.80%)
S&P 500   3,970.90 (+1.78%)
DOW   31,900.27 (+2.04%)
QQQ   292.20 (+1.22%)
AAPL   142.33 (+3.45%)
MSFT   259.44 (+2.72%)
FB   194.68 (+0.59%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.63 (-0.18%)
NIO   15.73 (-4.32%)
AMD   93.80 (+0.32%)
CGC   5.17 (-6.34%)
MU   69.22 (+0.46%)
T   20.84 (+2.16%)
GE   75.91 (+0.88%)
F   12.83 (+2.64%)
DIS   104.87 (+2.39%)
AMC   11.59 (-3.66%)
PFE   52.96 (+0.93%)
PYPL   81.10 (+0.70%)
NFLX   184.85 (-0.80%)
S&P 500   3,970.90 (+1.78%)
DOW   31,900.27 (+2.04%)
QQQ   292.20 (+1.22%)
AAPL   142.33 (+3.45%)
MSFT   259.44 (+2.72%)
FB   194.68 (+0.59%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.63 (-0.18%)
NIO   15.73 (-4.32%)
AMD   93.80 (+0.32%)
CGC   5.17 (-6.34%)
MU   69.22 (+0.46%)
T   20.84 (+2.16%)
GE   75.91 (+0.88%)
F   12.83 (+2.64%)
DIS   104.87 (+2.39%)
AMC   11.59 (-3.66%)
PFE   52.96 (+0.93%)
PYPL   81.10 (+0.70%)
NFLX   184.85 (-0.80%)
S&P 500   3,970.90 (+1.78%)
DOW   31,900.27 (+2.04%)
QQQ   292.20 (+1.22%)
AAPL   142.33 (+3.45%)
MSFT   259.44 (+2.72%)
FB   194.68 (+0.59%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.63 (-0.18%)
NIO   15.73 (-4.32%)
AMD   93.80 (+0.32%)
CGC   5.17 (-6.34%)
MU   69.22 (+0.46%)
T   20.84 (+2.16%)
GE   75.91 (+0.88%)
F   12.83 (+2.64%)
DIS   104.87 (+2.39%)
AMC   11.59 (-3.66%)
PFE   52.96 (+0.93%)
PYPL   81.10 (+0.70%)
NFLX   184.85 (-0.80%)
NASDAQ:BTAI

BioXcel Therapeutics (BTAI) Stock Forecast, Price & News

$13.37
-0.20 (-1.47%)
(As of 05/23/2022 01:47 PM ET)
Add
Compare
Today's Range
$12.95
▼
$13.77
50-Day Range
$9.67
▼
$21.99
52-Week Range
$9.08
▼
$39.00
Volume
7,415 shs
Average Volume
626,755 shs
Market Capitalization
$374.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.31
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive BTAI News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BioXcel Therapeutics logo

About BioXcel Therapeutics

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Headlines

May 20, 2022 | finance.yahoo.com
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference
May 19, 2022 | finance.yahoo.com
Why Shares of BioXcel Therapeutics Climbed 25.2% This Week
May 16, 2022 | americanbankingnews.com
BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $75.00 at Canaccord Genuity Group
May 13, 2022 | americanbankingnews.com
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) to Post Q2 2022 Earnings of ($1.32) Per Share, Jefferies Financial Group Forecasts
May 12, 2022 | americanbankingnews.com
BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $71.00
May 10, 2022 | finance.yahoo.com
BTAI: Data from TRANQUILITY II Trial in Late 2022 or Early 2023…
May 9, 2022 | seekingalpha.com
BioXcel stock falls as Q1 net loss widens Y/Y but Igalmi approval positions to "realize" FY22 goals
May 9, 2022 | finance.yahoo.com
BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights
May 7, 2022 | americanbankingnews.com
BioXcel Therapeutics (BTAI) Set to Announce Earnings on Monday
May 5, 2022 | finance.yahoo.com
Why BioXcel Therapeutics Shares Went Up 12.9% This Week
May 5, 2022 | finance.yahoo.com
BioXcel Therapeutics to Present at Three Upcoming Investor Conferences
May 3, 2022 | finance.yahoo.com
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
April 30, 2022 | finance.yahoo.com
2 Small-Cap Stocks With Monster Upsides, According to Wall Street
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BTAI
Previous Symbol
CUSIP
N/A
CIK
1720893
Web
www.bioxceltherapeutics.com
Phone
(475) 238-6837
Fax
N/A
Employees
89
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.93 per share
Price / Book
1.93

Profitability

EPS (Most Recent Fiscal Year)
($4.12)
Net Income
$-106.93 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-48.25%
Return on Assets
-45.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.98
Quick Ratio
12.93

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
27,985,000
Free Float
17,631,000
Market Cap
$374.16 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/09/2022
Today
5/23/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

2.22 out of 5 stars

Medical Sector

346th out of 1,416 stocks

Pharmaceutical Preparations Industry

136th out of 677 stocks

Analyst Opinion: 3.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

Is BioXcel Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioXcel Therapeutics stock.
View analyst ratings for BioXcel Therapeutics or view top-rated stocks.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for BioXcel Therapeutics.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its earnings results on Monday, May, 9th. The company reported ($1.12) earnings per share for the quarter, beating the consensus estimate of ($1.21) by $0.09. During the same period last year, the firm earned ($1.08) EPS.
View BioXcel Therapeutics' earnings history.

What price target have analysts set for BTAI?

6 analysts have issued 1 year price targets for BioXcel Therapeutics' shares. Their forecasts range from $24.00 to $110.00. On average, they anticipate BioXcel Therapeutics' stock price to reach $65.00 in the next year. This suggests a possible upside of 386.2% from the stock's current price.
View analysts' price targets for BioXcel Therapeutics or view top-rated stocks among Wall Street analysts.

Who are BioXcel Therapeutics' key executives?
BioXcel Therapeutics' management team includes the following people:
  • Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, & Director (Age 61, Pay $1.41M)
  • Dr. Frank D. Yocca Ph.D., Sr. VP & Chief Scientific Officer (Age 66, Pay $452.58k)
  • Mr. Javier Rodriguez, Sr. VP, Chief Legal Officer & Corp. Sec. (Age 50, Pay $470.53k)
  • Dr. Krishnan Nandabalan Ph.D., Chief Digital Officer ?& Director (Age 59, Pay $150k)
  • Mr. Richard I. Steinhart MBA, Sr. VP & CFO (Age 65)
  • Ms. Mary Coleman, VP of Investment Relations
  • Dr. Iris Francesconi Ph.D., Sr. VP of Marketing, Market Research & Commercial Assessments
  • Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 53)
  • Dr. Cedric Burg, VP and Head of Global Clinical Operations & Project Management
  • Mr. Matthew Wiley, Sr. VP & Chief Commercial Officer (Age 49)
What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Artemis Investment Management LLP (5.10%), State Street Corp (5.01%), BlackRock Inc. (4.58%), Vanguard Group Inc. (3.79%), Massachusetts Financial Services Co. MA (1.52%) and Northern Trust Corp (0.70%). Company insiders that own BioXcel Therapeutics stock include Bioxcel Llc, Frank Yocca, Vimal Mehta and Vincent O'neill.
View institutional ownership trends for BioXcel Therapeutics.

Which major investors are selling BioXcel Therapeutics stock?

BTAI stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., UBS Group AG, BlackRock Inc., HITE Hedge Asset Management LLC, Metropolitan Life Insurance Co NY, California State Teachers Retirement System, DAVENPORT & Co LLC, and Simplex Trading LLC. Company insiders that have sold BioXcel Therapeutics company stock in the last year include Bioxcel Llc, and Vimal Mehta.
View insider buying and selling activity for BioXcel Therapeutics or view top insider-selling stocks.

Which major investors are buying BioXcel Therapeutics stock?

BTAI stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, State Street Corp, Jane Street Group LLC, Apis Capital Advisors LLC, Vanguard Group Inc., Graham Capital Management L.P., PDT Partners LLC, and Worth Venture Partners LLC.
View insider buying and selling activity for BioXcel Therapeutics or or view top insider-buying stocks.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $13.37.

How much money does BioXcel Therapeutics make?

BioXcel Therapeutics has a market capitalization of $374.16 million. The company earns $-106.93 million in net income (profit) each year or ($4.12) on an earnings per share basis.

How many employees does BioXcel Therapeutics have?

BioXcel Therapeutics employs 89 workers across the globe.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at (475) 238-6837 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.